Proinflammatory cytokine interleukin-6 in prostate carcinogenesis
about
Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical reviewLinking obesogenic dysregulation to prostate cancer progression.Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro.Racial disparities in prostate cancer: a molecular perspective.c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.Avian leukosis virus subgroup J induces VEGF expression via NF-κB/PI3K-dependent IL-6 production.The ETS factor ESE3/EHF represses IL-6 preventing STAT3 activation and expansion of the prostate cancer stem-like compartment.NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence.Prostate-specific IL-6 transgene autonomously induce prostate neoplasm through amplifying inflammation in the prostate and peri-prostatic adipose tissue.Milk disrupts p53 and DNMT1, the guardians of the genome: implications for acne vulgaris and prostate cancer.Biological Effects of Hesperetin on Interleukin-6/Phosphorylated Signal Transducer and Activator of Transcription 3 Pathway Signaling in Prostate Cancer PC3 Cells.Cancer-associated fibroblasts enhance metastatic potential of lung cancer cells through IL-6/STAT3 signaling pathway.Androgen receptor signaling regulates T-type Ca2+ channel expression and neuroendocrine differentiation in prostate cancer cells.Exosomal microRNA profiling to identify hypoxia-related biomarkers in prostate cancer.Sprouty2 loss-induced IL6 drives castration-resistant prostate cancer through scavenger receptor B1.AIRE promotes androgen-independent prostate cancer by directly regulating IL-6 and modulating tumor microenvironment.
P2860
Q28073742-E9B5702A-C519-4553-BE97-69F4CC0F8934Q36300793-18726EF0-25B9-4C91-82C7-474778DDA6FBQ37185612-CB2D5B1B-80E5-4DB1-8C05-316545AF04F6Q37592047-E990B1DE-477A-45CE-A874-E1EF48508DF0Q37688990-0167CBCF-BD8C-4D85-AC40-AC1524B64856Q37696994-00A70D2B-38D0-45D8-806E-B7A1725E3724Q37718285-A6D38FE6-F85B-4584-AA1D-9B7CAC35E94BQ41022121-839CE13D-F642-461F-B5B6-2D413F88BF44Q41204113-343D212B-6854-4481-90B5-5EFB17A21CD5Q41396848-5246ED53-23F1-4061-BD64-9137AC09213CQ42280393-F0EE766D-EFA1-41E8-9DD9-DD8B45ADCFBAQ46763062-D40A9DD2-3954-4535-AD60-C99D74C88D0CQ53686355-B12D3664-3BAD-42B8-9FD7-51288360D84DQ54980135-D9578BB0-EB03-424F-9655-BD35BE35D033Q54982147-1809A226-9F04-46D0-A674-72B2235580F1Q55417295-F70FBE19-6F16-461D-AB24-26FC89897A97
P2860
Proinflammatory cytokine interleukin-6 in prostate carcinogenesis
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Proinflammatory cytokine interleukin-6 in prostate carcinogenesis
@en
type
label
Proinflammatory cytokine interleukin-6 in prostate carcinogenesis
@en
prefLabel
Proinflammatory cytokine interleukin-6 in prostate carcinogenesis
@en
P2860
P1476
Proinflammatory cytokine interleukin-6 in prostate carcinogenesis
@en
P2093
Zoran Culig
P2860
P304
P577
2014-10-02T00:00:00Z